Yan Fu

1.3k total citations
50 papers, 994 citations indexed

About

Yan Fu is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Yan Fu has authored 50 papers receiving a total of 994 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Molecular Biology and 14 papers in Surgery. Recurrent topics in Yan Fu's work include Inflammatory Biomarkers in Disease Prognosis (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Cancer, Lipids, and Metabolism (5 papers). Yan Fu is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (7 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Cancer, Lipids, and Metabolism (5 papers). Yan Fu collaborates with scholars based in China, United States and South Korea. Yan Fu's co-authors include Weidong Tong, Fan Li, Heling Wang, Qi Su, Changjun Yin, Chao Qin, Hui Zhao, Nan Du, Meilin Wang and Ankui Yang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Yan Fu

49 papers receiving 983 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yan Fu China 19 499 279 233 218 208 50 994
Mărioara Cornianu Romania 16 298 0.6× 204 0.7× 208 0.9× 216 1.0× 128 0.6× 66 778
Feng Luo China 16 477 1.0× 168 0.6× 276 1.2× 133 0.6× 157 0.8× 61 943
Stefan Stremitzer Austria 22 563 1.1× 288 1.0× 167 0.7× 450 2.1× 156 0.8× 76 1.2k
Tomoyuki Nakagiri Japan 20 332 0.7× 618 2.2× 181 0.8× 386 1.8× 133 0.6× 64 1.3k
Vlad Herlea Romania 20 424 0.8× 224 0.8× 367 1.6× 389 1.8× 313 1.5× 120 1.2k
Takanori Ochiai Japan 20 469 0.9× 215 0.8× 270 1.2× 329 1.5× 212 1.0× 73 1.1k
Yongjie Shui China 15 206 0.4× 154 0.6× 207 0.9× 146 0.7× 75 0.4× 32 648
Matteo Palmeri Italy 17 582 1.2× 401 1.4× 147 0.6× 559 2.6× 117 0.6× 70 1.1k
Shijie Zhou China 16 197 0.4× 366 1.3× 441 1.9× 119 0.5× 255 1.2× 68 1.0k
Kazuo Okadome Japan 12 564 1.1× 272 1.0× 264 1.1× 385 1.8× 136 0.7× 24 996

Countries citing papers authored by Yan Fu

Since Specialization
Citations

This map shows the geographic impact of Yan Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Fu more than expected).

Fields of papers citing papers by Yan Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Fu. The network helps show where Yan Fu may publish in the future.

Co-authorship network of co-authors of Yan Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Fu. A scholar is included among the top collaborators of Yan Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Fu. Yan Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Xia, Xian Gao, Jiaqi Ding, et al.. (2024). Fecal microbiota transplantation alleviates mild‐moderate COVID‐19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double‐blind clinical trial. Journal of Medical Virology. 96(8). e29812–e29812. 6 indexed citations
2.
3.
An, Chao, Yan Fu, Wang Li, Mengxuan Zuo, & Peihong Wu. (2023). Postprogression treatment of lenvatinib plus PD‐1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. Cancer. 129(14). 2235–2244. 13 indexed citations
4.
Fu, Yan, et al.. (2023). Infigratinib, a Selective Fibroblast Growth Factor Receptor Inhibitor, Suppresses Stent-Induced Tissue Hyperplasia in a Rat Esophageal Model. CardioVascular and Interventional Radiology. 46(9). 1267–1275. 4 indexed citations
5.
Gu, Hui-Yun, Zhen-Dong Huang, Qiong Zhang, et al.. (2019). Impact of Enhanced Recovery After Surgery on Postoperative Recovery for Pancreaticoduodenectomy: Pooled Analysis of Observational Study. Frontiers in Oncology. 9. 687–687. 22 indexed citations
6.
Fu, Yan, et al.. (2018). Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: A meta-analysis. International Journal of Surgery. 55. 128–138. 127 indexed citations
7.
Jia, Youchao, Zhigang Wang, Aimin Zang, et al.. (2016). Tetramethylpyrazine inhibits tumor growth of lung cancer through disrupting angiogenesis via BMP/Smad/Id-1 signaling. International Journal of Oncology. 48(5). 2079–2086. 29 indexed citations
8.
Fu, Yan, Wei Wei Liu, Dian Ouyang, Ankui Yang, & Quan Zhang. (2016). Preoperative Neutrophil-to-lymphocyte Ratio Predicts Long-term Survival in Patients Undergoing Total Laryngectomy With Advanced Laryngeal Squamous Cell Carcinoma. Medicine. 95(6). e2689–e2689. 38 indexed citations
9.
Fu, Yan, Jia Hu, Nan Du, et al.. (2015). Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. Journal of Chemotherapy. 28(3). 218–224. 21 indexed citations
10.
Zhao, Hui, Xiaosong Li, Dianjun Chen, et al.. (2015). Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Medical Oncology. 32(2). 292–292. 25 indexed citations
11.
Fu, Yan, Hui Zhao, Jia Hu, et al.. (2015). Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib.. PubMed. 8(5). 8288–94. 34 indexed citations
12.
Du, Nan, Xiaosong Li, Fang Li, et al.. (2013). Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncology Reports. 29(6). 2332–2340. 74 indexed citations
13.
Yang, Qin, et al.. (2012). Effects of biological factors on fruit and seed set in loquat ( Eriobotrya japonica Lindl.). African Journal of Agricultural Research. 7(38). 5303–5311. 5 indexed citations
14.
Chu, Haiyan, Yan Fu, Lan Ma, et al.. (2012). Polymorphisms in the IL-13 and IL-4R genes are associated with the development of renal cell carcinoma. Annals of Oncology. 23(8). 2114–2121. 25 indexed citations
15.
Shi, Danni, Pu Li, Lan Ma, et al.. (2012). A Genetic Variant in pre-miR-27a Is Associated with a Reduced Renal Cell Cancer Risk in a Chinese Population. PLoS ONE. 7(10). e46566–e46566. 38 indexed citations
16.
Fu, Yan, et al.. (2011). NEDD9 Gene Polymorphism Influences the Risk of Alzheimer Disease and Cognitive Function in Chinese Older Persons. Alzheimer Disease & Associated Disorders. 26(1). 88–90. 4 indexed citations
17.
Zhao, Hu, Chao Qin, Yan Fu, et al.. (2010). hOGG1 Ser326Cys Polymorphism and Renal Cell Carcinoma Risk in a Chinese Population. DNA and Cell Biology. 30(5). 317–321. 14 indexed citations
18.
Zhu, Jian, Xianghong Ju, Yan Fu, et al.. (2010). Association of IL‐4 −590 T>C polymorphism and risk of renal cell carcinoma in a Chinese population. International Journal of Immunogenetics. 37(6). 459–465. 9 indexed citations
19.
Zhu, Jian, Chao Qin, Yan Fu, et al.. (2010). IL‐16 polymorphism and risk of renal cell carcinoma: Association in a Chinese population. International Journal of Urology. 17(8). 700–707. 23 indexed citations
20.
Fu, Yan, et al.. (2009). Lack of association of neprilysin gene polymorphisms with Alzheimer's disease in a southern Chinese community. International Psychogeriatrics. 21(2). 354–358. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mărioara Cornianu Breakdown of academic impact, for papers by Feng Luo Breakdown of academic impact, for papers by Stefan Stremitzer Breakdown of academic impact, for papers by Tomoyuki Nakagiri Breakdown of academic impact, for papers by Vlad Herlea Breakdown of academic impact, for papers by Takanori Ochiai Breakdown of academic impact, for papers by Yongjie Shui Breakdown of academic impact, for papers by Matteo Palmeri Breakdown of academic impact, for papers by Shijie Zhou Breakdown of academic impact, for papers by Kazuo Okadome
Rankless by CCL
2026